Mayne Pharma Group Limited Stock

Equities

MYX

AU000000MYX0

Pharmaceuticals

Market Closed - Australian S.E. 02:10:36 2024-05-13 am EDT 5-day change 1st Jan Change
7.07 AUD +0.86% Intraday chart for Mayne Pharma Group Limited -4.07% +14.96%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2024 * 384M 254M Sales 2025 * 429M 284M Capitalization 574M 379M
Net income 2024 * -83M -54.85M Net income 2025 * -2M -1.32M EV / Sales 2024 * 1.31 x
Net cash position 2024 * 72.1M 47.64M Net cash position 2025 * 60.91M 40.25M EV / Sales 2025 * 1.19 x
P/E ratio 2024 *
-6.91 x
P/E ratio 2025 *
-206 x
Employees 967
Yield 2024 *
-
Yield 2025 *
-
Free-Float 70.67%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.86%
1 week-4.07%
Current month+1.43%
1 month+0.14%
3 months+30.93%
6 months+71.60%
Current year+14.96%
More quotes
1 week
7.00
Extreme 7
7.43
1 month
6.50
Extreme 6.5
7.46
Current year
5.00
Extreme 5
7.46
1 year
2.75
Extreme 2.75
7.46
3 years
0.22
Extreme 0.22
8.50
5 years
0.22
Extreme 0.22
12.90
10 years
0.22
Extreme 0.22
42.20
More quotes
Managers TitleAgeSince
Chief Executive Officer - 22-09-30
Director of Finance/CFO - 22-08-28
Chief Tech/Sci/R&D Officer - 14-12-31
Members of the board TitleAgeSince
Chairman 70 18-05-29
Director/Board Member 59 18-06-27
Chief Executive Officer - 22-09-30
More insiders
Date Price Change Volume
24-05-13 7.07 +0.86% 72 172
24-05-10 7.01 -1.54% 85,754
24-05-09 7.12 -0.28% 159,902
24-05-08 7.14 -1.79% 117,353
24-05-07 7.27 0.00% 87,693

Delayed Quote Australian S.E., May 13, 2024 at 02:10 am EDT

More quotes
Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on commercializing novel pharmaceuticals. The Company also provides contract development and manufacturing services to clients worldwide. The Company’s segments include Women’s Health, Dermatology, and International. The Women’s Health segment distributes women’s health branded products in the United States. This segment includes NEXTSTELLIS, ANNOVERA, BIJUVA, IMVEXXY and branded pre-natal vitamins. The Dermatology segment distributes established dermatology products in the United States. The International segment is engaged in the manufacture and sale of branded and generic pharmaceutical products globally and the provision of contract development and manufacturing services to third party customers. The Company's products include ACTIKERALL Solution, ASTRIX Capsules and Tablets, MAGNOPLASM Paste and SPLINTEX Splinter Removal Gel, and ANNOVERA Vaginal Ring, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
7.07 AUD
Average target price
7.035 AUD
Spread / Average Target
-0.50%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW